Conference Coverage
Conference Coverage
Lipid-lowering bempedoic acid does not hasten or worsen diabetes
The “study is important as it shows overall consistent efficacy and safety [of this lipid-lowering drug] regardless of glycemic status and no...
Conference Coverage
Dapagliflozin’s T2D renal protection extends to ‘fast decline’ of eGFR
Another dimension of dapagliflozin’s renal protection for type 2 diabetes patients is shown in a post-hoc analysis from its cardiovascular...
Conference Coverage
VERTIS-CV: Ertugliflozin’s CV outcomes trial confirms SGLT2i benefits
Conference Coverage
Frequent hypoglycemic episodes raise cardiac event risk
It’s “essential” to avoid drugs associated with hypoglycemia to minimize CV event risk in patients with type 2 diabetes, investigator says.
Conference Coverage
Novel insulin shows early promise for once-weekly treatment
With similar efficacy and safety to insulin glargine U100, if findings are confirmed in phase 3 and product is approved, it could be the first-...
Conference Coverage
CAC scoring pinpoints stenoses in asymptomatic diabetes patients
Conference Coverage
DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients
Conference Coverage
For COVID-19 plus diabetes, glycemic control tops treatment list
Tight glucose control led to better results in patients with diabetes and COVID-19.
Conference Coverage
Diabetes hospitalizations halved with FreeStyle Libre glucose monitor
Hospitalizations for diabetic ketoacidosis, diabetes-related emergencies, and all-cause hospitalizations were reduced following initiation of...
Conference Coverage
CV outcomes of SGLT2 inhibitors and GLP-1 agonists compared in real-world study